ABSTRACT
Introduction
The medical burden of the elderly Japanese population is increasing very rapidly, with people aged > 75 years now accounting for >10% of the population [1] . With an increasingly aged population, morbidity and mortality due to various cancers, including malignant lymphoma, among people aged > 70 years will also increase. In 2000, the age-specific incidence rates of malignant lymphoma in Japan were 56 -81 per 100,000 populations among men aged > 75 years and approximately 30 per 100,000 populations among women aged > 75 years [2] .
Patients with malignant lymphoma can follow various clinical courses and prognoses, depending on their histological subtype. Some of subtypes of malignant lymphoma are now curable with the development of new therapeutic options. However, age has been recognized as one of the strongest adverse prognostic indicators in patients with malignant lymphoma [3] [4] [5] . One of reasons for this is that elderly patients sometimes receive insufficient therapy due to factors such as chronic comorbid conditions, poor performance status (PS), and abnormal organ function. In practice, physicians can have difficultly choosing the optimal management for very elderly patients, in terms of which medication and what dose. Although many studies have reported data for lymphoma patients aged 60 -80 years, there is relatively little evidence for the management of very elderly patients. We have therefore analyzed the relationships between clinical characteristics, comorbidities, treatment and outcome in patients with malignant lymphoma aged > 75 years.
Patients and Methods

Patients, Clinical Assessment and Treatment
From January 1998 to March 2007, 435 patients with malignant lymphoma, diagnosed according to REAL [8, 9] ) and the hematopoietic cell transplantation comorbidity index (HCTCI) [10] . Over the study period, the standard treatment at our institute was a pirarubicin, cyclophosphamide, vincristine and prednisolone (THP-COP) or THP-COP-like regimen with or without rituximab. The doses and schedules of THP-COP and rituximab according to age are shown in Table 1 . Some patients with localized lymphoma received three cycles of THP-COP following involved field irradiation. Patients with advanced lymphoma were planned to receive at least six cycles of THP-COP. For patients with poor PS, physicians modified the dose according to their own judgment. The cycle duration was also modified at the physician's discretion (≥21 days, depending on the grade of myelosuppression and adverse events). For some patients, in the absence of institutional policy, the choice of treatment (including palliative care) was based on the referring physician's judgment and the patient's wishes. General condition and coexisting organ dysfunction were the major criteria that affected treatment decisions. The patients and their outcomes have been followed closely, and where possible, the cause of death has been identified.
Relative Dose Intensity
We analyzed the agent-specific relative dose intensity (RDI) [11] as the ratio of the dose actually delivered to the planned dose intensity in 64 malignant lymphoma patients who received a THP-COP or THP-COP-like regimen ± rituximab. The average RDI (aRDI) was calculated by averaging the delivered RDI of cyclophos phamide and pirarubicin for THP-COP ± rituximab. We analyzed overall survival comparisons of three groups 
Statistical Analysis
The relationships between age and sex, PS, stage, IPI, therapy and comorbidity index was analyzed using the student's t-test. Overall survival was calculated from the date of diagnosis to the date of death according to the method of Kaplan and Meier [13] . Comparisons were made using a log-rank test with the following variables: age, sex, PS, stage, serum LDH level, immunophenotype of lymphoma, IPI and comorbidity index (by HCTCI and CCI) in all patients. We also analyzed overall survival comparisons of the above variables, except for comorbidity index, along with use or not of rituximab in patients with diffuse large B-cell lymphoma.
Results
Patient Characteristics and Relationship between Age and Clinical Variables
The clinical characteristics of the patients are summarized in Table 2 . The median follow-up period was 659 days. The mean age was 79.9 years (range 75 -89 years). Poor PS (2-4), advanced stage (III or IV), raised LDH and high-intermediate and high risk IPI were seen in 41%, 56%, 55%, and 53% of patients, respectively. According to the WHO classification, 68 of 98 patients (69.4%) presented a B-cell lymphoma ( Table 3) . The most frequent histological subtype was diffuse large B-cell lymphoma (n = 48). It is noteworthy that the proportion of adult T-cell leukemia/lymphoma (ATL) was relatively high (n = 12), because the Saga prefecture area of Japan, where the study was carried out, is an endemic area of human T-cell leukemia virus type 1 (HTLV-I). When patients were divided into three groups (standard chemotherapy, radiation alone, and palliative therapy), there was a trend towards a relationship between age and palliative care versus chemotherapy (p = 0.056), but no relationship between age and other combinations of treatment. This suggests that physicians tended not to select aggressive chemotherapy for older patients. There was no significant correlation between age and other clinical variables (sex, subtype, PS, stage and IPI).
Survival Analysis
The 5-year overall survival rate was 32.2% among 97 malignant lymphoma patients (Figure 1(a) ). Median survival time was 378 days among 62 deceased patients. The main reasons for death were malignant lymphoma (n = 27, 43.5%), infection ( = 4, 6.5%) and other man Table 2) . Among DLBCL patients, 5-year overall survival rate was 36.6% (Figure 1(b) ). The overall survival rate was significantly higher in the following groups: female, stage I/II, normal serum LDH level, low/low-intermediate IPI, and age ≥ 80 vs. ≤ 79 years ( Table 2) .
Thirty-nine patients with DLBCL received a THP-COP or THP-COP-like regimen, and 23 of these also received rituximab. The 5-year overall survival rate was significantly higher among patients who received chemotherapy in combination with rituximab than among those who did not receive rituximab (40.9% vs 16.7%, p < 0.05).
Relationship between Comorbidity and Survival
Major comorbidities according to HCTCI and CCI are summarized in Table 4 . Seventy-three patients (75%) had more than one comorbidity. A previous history of cardiovascular diseases (including arrhythmia, angina pectoris, myocardial infarction, cardiac failure, pacemaker, and valve disease) was found in 28 patients. Diabetes Copyright © 2011 SciRes. IJCM was found in 10 and cerebrovascular disease was found in 19 patients. Prior or simultaneous malignnant disease was found in 22 patients. Patients were separated into three categories: 0, 1, 2, and ≥3 according to the original description of the HCTCI and CCI scoring systems. Overall survival was significantly poorer among patients with infection and moderate/severe liver dysfunction ( Table 4) , but the HCTCI and CCI score did not impact overall survival. (Figure 2) 
Relative Dose Intensity in Elderly Malignant Lymphoma
In this study, 64 or 97 patients received a THP-COP or THP-COP-like regimen. We analyzed aRDI for these patients. Status, subtype, and outcome profiles in these patients are shown in Figure 3 . Of 31 patients with advanced aggressive lymphoma, 21 had B-cell lymphomas and 10 had T-cell lymphomas. Sixteen patients accomplished six cycles of THP-COP. However, only three patients (9.7%) with these advanced aggressive lymphomas had an aRDI for cyclophospamide and pirarubicin ≥ 0.85. Fifteen patients stopped THP-COP, due to exacerbation of lymphoma (n = 9), adverse effects (n = 2), changing hospital (n = 3), and patient's decision (n = 1). The proportion of patients receiving ≥ 0.85 of the planned dose intensity during five cycles of treatment decreased gradually across cycles of chemotherapy (Figure 4) . Furthermore, the proportions of patients with RDI ≥ 0.85 in the first cycle of chemotherapy were < 50% in all patient who received THP-COP and in the 31 patients with advanced aggressive lymphoma. The prognosis of patients with advanced aggressive lymphoma who completed their THP-COP regimen was better than those who did not complete the regimen. However, overall survival was not significant different between those with aRDI ≥ 0.85 or ≤ 0.84.
Discussion
The population in Saga prefecture where our hospital is located is approximate 852,000 in the 2009 national population census. Of these, 12.9% were >75 years old, which is higher than average in Japan. However, this is likely to be the case in the rest of Japan in near future. The consultation rate of elderly hematological patients at our hospital is high, and the number of patients with lymphoma was 2 to 3-fold higher in 2005-2007 than it was in 1998-2000. Numerous studies about clinical presentation for very elderly patients with malignant lymphoma have been reported from western countries [14] [15] [16] [17] [18] [19] , but there is limited practical information in Japan. It is therefore very important to analyze the current picture of lymphoma patients in Japan and to be aware of this issue, in order to be prepared for the aging Japanese society. We analyzed a relationship between age and clinical index, including PS, stage, comorbidity, histology, and initial therapy. There were no significant differences between age and clinical indexes, except for initial therapy. Some of patients, their family and physician chose palliative or no chemotherapy rather than aggressive chemotherapy for older patients on ground of patients' will and lack confidence in receiving chemotherapy. They tended to select the therapy based on age, even if PS and comorbidities were not poor. Elderly patients could not always understand the benefits and detriments of therapy, despite adequate information, because most of them have a reduced emotional tolerance about their disease diagnosis and its treatment. Therefore, a patient's family often decided the best therapy for the patient. Also, some of the patients were conscious of their age, and some refused chemotherapy on the basis of their advanced age. However, there was no significant difference between those aged ≤ 79 years compared with those aged ≥ 80 years group in our study. Furthermore, the prognosis of the elderly patients was actually quite reasonable. These factors may make the chance of cure less likely, and shorten the survival time for patients with curable lymphoma. Aging is not a reason not to choose aggressive chemotherapy, as has been showed in other studies [17, 20] .
Comorbidity index (using HCTCI and CCI) is an important prognostic factor in elderly acute myelogenous leukemia (AML) patients and stem cell transplantation [9, [21] [22] [23] . However, there are few data on whether comorbidity index is a useful prognostic factor in elderly lymphoma patients. We found that both HCTCI and CCI were not significantly prognostic, except for infection and severe liver disease. This finding suggests that some of subtypes of lymphoma are curable, if elderly patients receive reduced-intensity chemotherapy. Comorbidity index is, therefore, a useful predictive prognostic marker in diseases that require strong chemotherapy, such as elderly AML and stem cell transplantation, but not for elderly malignant lymphoma. Once a complete remission has been achieved, the disease-free survival can be similar to that of a younger patient, even if the first-line chemotherapy regimen was less aggressive [24] . Other studies have also reported that CCI is not associated with survival in retrospective analyses [14, 18] .
In contrast, PS was one of the most important vari-ables predictive of survival. PS reflects tolerance of patients, organ function, and disease progression, and it is the most important factor for judging whether patients can receive aggressive chemotherapy. Comorbidity index may be prognostic factor, as with PS, in some lymphoma subtypes, but comorbidity index needs to be evaluated in prospective trials of patients with each subtype to confirm this. Our data suggest that lymphoma phenotype is a strong prognostic factor. Patients with T/NK cell lymphoma had a very inferior prognosis compared with patients with B-cell lymphoma. Our geographic area is endemic for HTLV-I, and elderly ATL is frequently diagnosed. Aggressive ATL generally has a poor prognosis and it is difficult to prolong the survival time even with intensive chemotherapy [25] . Allogeneic hematopoietic stem cell transplantation is now considered a promising treatment for young patients with ATL [26, 27] , but is not indicated in elderly patients due to higher toxicities and poor completion rates. Currently, chemotherapy for elderly ATL patients should focus on safety above efficacy, because this disease is not curable.
Some reports have shown that maintaining a high RDI of doxorubicin provides a survival benefit [11, 12, 28] . Lyman et al. showed that a subset of patients aged > 60 years who were treated with doxorubicin at dose intensities > 10 mg/m 2 /week had a 5-year survival rate similar to that seen in younger patients [12] . However, in patients aged > 75 years old, it is difficult to maintain dose intensity because most elderly patients have some comorbid disease and poor PS. Indeed, only 10% of the patients with aggressive lymphoma in our study who received a THP-COP or THP-COP-like regimen managed to maintain RDI > 0.85. This was partly due to a prolonged recovery of bone marrow after chemotherapy, but also due to insufficient dosing. This is particularly problematic for elderly patients due to problems getting to the hospital and the absence of a care assistant at home. However, patients treated at RDI ≤ 0.84 in the > 75-year old group did not have a significantly poorer outcome. This may be due to the small number of patients in this study. However, to the best of our knowledge, this is the first study to focus on very elderly lymphoma patients. Our findings suggest that it is preferable to carry on treatment at a lower dose, thereby minimizing adverse events, rather than strictly adhering to high dose intensity. However, a large-scale study is recommended in order to validate this proposal.
In conclusion, age is not always an adverse prognostic factor, if the patient has good PS, favorable histology, and lower-risk IPI. As is the case in younger patients, the most important prognostic factors were lymphoma subtype, PS, and IPI. Comorbidity index, however, did not have an impact on survival. Maintaining a high RDI during chemotherapy is recommended, but in practice, this can be difficult. Modification of the applied dose and the duration of chemotherapy may be required to improve survival in very elderly patients.
